Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma

Shi, Xiaoxiao; Miao, Weimin; Pang, Diwen; Wu, Jiasi; Tong, Qi-Song; Li, Jiaxian; Luo, Jiaqi; Li, Wenyu; Du, Jin‐Zhi; Wang, Jun

doi:10.1039/c9bm01750j

Cited by 28 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As such, a study from 2019 tried to reconciliate these features by synthesizing conjugated nanoparticles loaded with DOX for the treatment of PCNSL [130]. In their study, the authors used an approach previously reported in the literature which aimed to target lowdensity lipoprotein receptor-related protein (LRP) [131].…”

Section: Primary Central Nervous System Lymphoma (Pcnsl)-enhancing Bbb Crossingmentioning

confidence: 99%

Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases

Faouzi

Roullin

2021

Pharmaceuticals

View full text Add to dashboard Cite

The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB), which both act as biochemical, dynamic obstacles impeding any type of undesirable exogenous exchanges. The disruption of these barriers is usually associated with the development of neuropathologies which can be the consequence of genetic disorders, local antigenic invasions, or autoimmune diseases. These disorders can take the shape of rare CNS-related diseases (other than Alzheimer’s and Parkinson’s) which a exhibit relatively low or moderate prevalence and could be part of a potential line of treatments from current nanotargeted therapies. Indeed, one of the most promising therapeutical alternatives in that field comes from the development of nanotechnologies which can be divided between drug delivery systems and diagnostic tools. Unfortunately, the number of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly due to a lack of interest from industrial pharmaceutical companies. In the present review, we will provide an overview of some of these rare CNS diseases, discuss the physiopathology of these disorders, shed light on how nanotherapies could be of interest as a credible line of treatment, and finally address the major issues which can hinder the development of efficient therapies in that area.

show abstract

Section: Primary Central Nervous System Lymphoma (Pcnsl)-enhancing Bbb Crossingmentioning

confidence: 99%

Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases

Faouzi

Roullin

2021

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Another recent study of ginsenoside Rg3 and thioflavin T delivery reported that angiopep-2-conjugated PLGA NPs allowed the encapsulated compounds to cross the BBB and reach glial cells, exhibiting neuroprotective effects based on its antioxidant, anti-inflammatory, antiapoptotic, and anti-Aβ plaque activities in an in vitro BBB model [ 174 ]. The angiopep-2 ligand can specifically bind to low-density lipoprotein receptor-related protein-1 (LRP-1) on the surface of the brain capillary endothelial cells, thereby facilitating cellular uptake across the BBB via receptor-mediated endocytosis [ 174 , 175 ].…”

Section: Various Nanocarriers Containing Natural Compounds For Thementioning

confidence: 99%

The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation

et al. 2020

View full text Add to dashboard Cite

Neuroinflammation, which is involved in various inflammatory cascades in nervous tissues, can result in persistent and chronic apoptotic neuronal cell death and programmed cell death, triggering various degenerative disorders of the central nervous system (CNS). The neuroprotective effects of natural compounds against neuroinflammation are mainly mediated by their antioxidant, anti-inflammatory, and antiapoptotic properties that specifically promote or inhibit various molecular signal transduction pathways. However, natural compounds have several limitations, such as their pharmacokinetic properties and stability, which hinder their clinical development and use as medicines. This review discusses the molecular mechanisms of neuroinflammation and degenerative diseases of CNS. In addition, it emphasizes potential natural compounds and their promising nanocarriers for overcoming their limitations in the treatment of neuroinflammation. Moreover, recent promising CNS inflammation-targeted nanocarrier systems implementing lesion site-specific active targeting strategies for CNS inflammation are also discussed.

show abstract

“…Thus, the BBB is a physiologic barrier that limits the passage of most molecules in order to protect the stability of the brain. 13,14 Similarly, the BBB limits the entry into the brain of many contrast agents that could improve the diagnosis and evaluation of brain diseases, including brain tumors.…”

Section: Introductionmentioning

confidence: 99%

“…[21][22][23][24] The angiopep family of peptides can also cross the BBB via a low-density lipoprotein receptor-related protein (LRP) mediated pathway. 13,25 Among them, angiopep-2 with a molecular weight of 2.4 kDa promotes receptor-mediated transport through LRP1, resulting in higher in vivo and in vitro transcytosis capacity than other targeting ligands. 26,27 Angiopep-2 can also target gliomas due to the high expression of LPR1 on the surface of glioma cells.…”

Section: Introductionmentioning

confidence: 99%

Small functionalized iron oxide nanoparticles for dual brain magnetic resonance imaging and fluorescence imaging

et al. 2021

View full text Add to dashboard Cite

show abstract

Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma

Abstract: APP nanoparticle was developed to deliver DOX for the treatment of PCNSL. The results indicated that APP@DOX could overcome the BBB, and significantly prolong the survival time of mice with an intracranial SU-DHL-2 lymphoma xenograft.

Cited by 28 publications

References 38 publications

Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases

Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases

The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation

Small functionalized iron oxide nanoparticles for dual brain magnetic resonance imaging and fluorescence imaging

Contact Info

Product

Resources

About